ARI0003 / August Pi i Sunyer Biomedical Research Institute - LARVOL DELTA

Choosing the right double-barreled gun: ARI0003 takes aim at lymphoma by targeting both CD19 and BCMA. (PubMed, Mol Ther) - No abstract available

Journal • Hematological Malignancies • Lymphoma • Oncology

ARI0003: Co-transduced CD19/BCMA Dual-targeting CAR-T Cells for the Treatment of Non-Hodgkin Lymphoma. (PubMed, Mol Ther) - P1 | "We optimized different dual-targeting approaches, including co-transduction of two lentiviral vectors, bicistronic, tandem, loop and pool strategies, based on our academic anti-CD19 (ARI0001) and anti-BCMA (ARI0002h) CAR-T cells. ARI0003 CAR-T cells were effectively manufactured under Good Manufacturing Practice conditions, with reduced risk of genotoxicity compared to other dual-targeting approaches. A first-in-human phase I clinical trial (CARTD-BG-01, NCT06097455) has been initiated to evaluate the safety and efficacy of ARI0003 in NHL."

CAR T-Cell Therapy • IO biomarker • Journal • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD22

In March, the Clínic will begin a pioneering trial worldwide with its third CAR-T in lymphoma [Google translation] (GacetaMedica) - "The Hospital Clínic-IDIBAPS has announced that next Tuesday, March 5, it will begin a pioneering clinical trial worldwide with ARI-0003, a CAR-T for lymphoma. It is a dual CAR-T and targets two therapeutic targets present on malignant cells: CD-19 and BCMA. In the words of Álvaro Urbano-Ispizua, coordinator of the hospital's CAR-T Program 'It is the sum of the two CAR-Ts that the hospital already has, ARI-0001, directed against the CD-19 receptor of lymphocytes, and ARI-0002h, which targets the BCMA receptor and is used for the treatment of myeloma.' 35 patients diagnosed with lymphoma will participate in the study....In this sense, in addition to ARI-0001, for the treatment of acute lymphoblastic leukemias and lymphomas, ARI-0002h, for multiple myeloma and ARI-0003, for lymphoma, in the coming months, a trial will also begin with CAR-T HER2 for the treatment of breast cancer."

New trial • Acute Lymphocytic Leukemia • Breast Cancer • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Oncology • Solid Tumor

ARI0003, a Novel Dual CD19 and BCMA-targeted CAR T-cell Therapy (EBMT-EHA 2024) - "The production of GMP-grade ARI0003 was feasible, with the potential for translation into clinical practice for aggressive B-cell lymphomas, including patients after anti-CD19 CAR-T failure."

CAR T-Cell Therapy • IO biomarker • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD4 • CD8

CARTD-BG-1: First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Fundacion Clinic per a la Recerca Biomédica

New P1 trial • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF17